New Study Demonstrates Long-term Effectiveness Of Centinel Spine's Prodisc® L Total Disc Replacement

웨스트 체스터, 펜실베니아., 8 월 31, 2021 /PRNewswire/ — 센티넬 스파인^®, LLC, a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced findings of a new study first presented at the annual meeting of the International Society for the Advancement of Spinal Surgery (ISASS) (May 13-15, 2021, 마이애미, FL). 티에리 마르네이, MD reported results that strongly support the long-term safety and effectiveness of Centinel Spine’s pro디스크® L Total Disc Replacement System for the lumbar spine. Results from this study will be further presented during the Best Paper session at the upcoming North American Spine Society (NASS) 36^th Annual Meeting on 9월 (목요일) 30, 2021.

The study expands the evidence of pro디스크 L and is one of the largest total disc replacement patient groups ever evaluated—demonstrating the robust long-term clinical success of one- and two-level lumbar total disc replacement (TDR) with pro디스크 L, as assessed at 7-21 years postoperatively. A total of 1,187 patients who underwent lumbar TDR from 1999 to 2013 were followed. Until this study, lumbar TDR published evidence was limited to 5-7 year follow up.

According to the study, patients had maintained reduction in disability and pain scores over time, with low rates of index revision/reoperation or adjacent level surgery when compared to long-term published fusion data. Total TDR revision and adjacent level surgery rates over 7-21 years were 0.67% and 1.85%, respectively (Marnay, Thierry. “7 to 21 year clinical outcomes of 1,187 patients treated with one and two level lumbar total disc arthroplasty”, ISASS 2021 Annual Meeting, 2021 년 5 월 14 일, 마이애미, FL).

센티넬스파인 대표이사 스티브 머레이, stated, “This study reinforces the long-term safety and effectiveness of the pro디스크 system, a motion preservation technology that supports the advancement of patient care. The pro디스크 technology was designed on proven design principles and this study demonstrates continued positive results after over 30 years of clinical usage.”

Centinel Spine continues to lead the total disc replacement market and is the only company with FDA-approved cervical and lumbar total disc replacement devices. The pro디스크 L remains the only total disc replacement system in the U.S. approved for two-level use in the lumbar spine.

센티넬 스파인, LLC 소개

센티넬 척추^®, LLC is a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access. The company offers a continuum of trusted, brand-name, motion-preserving and fusion solutions backed by over 30 years of clinical success—providing the most robust and clinically-proven technology platforms in the world for total disc replacement (pro디스크®) 및 통합 인터바디^™ 융합(스탈리프®).

Centinel Spine은 척추 산업의 변화를 주도하고 척추 수술에 대한 인식을 바꾸려는 선구적인 문화와 기업 사명을 계속 발전시키고 있습니다. Centinel Spine은 경추 및 요추 전방 기둥 재건을 위한 포괄적인 동작 보존 및 융합 솔루션을 제공하는 유일한 회사입니다.

자세한 내용은 회사 웹 사이트를 방문하십시오. www.CentinelSpine.com 또는 문의 :

바룬 간디
최고 재무담당자(CFO)
900 Airport Road, 스위트룸 3B
웨스트 체스터, 펜실베이니아 주 19380
전화번호 :484-887-8871
이메일 : v.gandhi@centinelspine.com